Idarucizumab reversal of dabigatran expands stroke reperfusion options by enabling both IVT and EVT in NOAC-treated patients.
Idarucizumab reversal can safely enable both intravenous thrombolysis and endovascular thrombectomy in patients experiencing acute ischemic stroke while on dabigatran.
This case illustrates how idarucizumab reversal expands reperfusion options by enabling both IVT and EVT in NOAC-treated patients and highlights the diagnostic role of EVT in revealing underlying vascular pathology, emphasizing the need for individualized post-procedural antithrombotic management.
Sari et al. (2025) studied this question. Idarucizumab reversal of dabigatran expands stroke reperfusion options by enabling both IVT and EVT in NOAC-treated patients.